Preemptive alcohol septal ablation prior to transcatheter mitral valve replacement
Catheterization and Cardiovascular Interventions · 2023-12 · 102 (7) · 1341-1347
DOI: 10.1002/ccd.30879 ↗At a glance
Journal article in Catheterization and Cardiovascular Interventions, published online on 2023-10-19. Written by Ningyan Wong and 5 co-authors. Institution: Advanced Cardiac Valve Center, University of Virginia, Charlottesville, Virginia, USA. Major MEDLINE topics: Heart Valve Prosthesis Implantation, Heart Valve Prosthesis, Ventricular Outflow Obstruction, Left, Ventricular Outflow Obstruction. Cited 3 times so far (Crossref); 29 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Background
Alcohol septal ablation (ASA) has been shown to increase the neo‐left ventricular outflow tract (LVOT) area before transcatheter mitral valve replacement (TMVR) but there is little literature on its success and use with dedicated devices.
Aims
To describe our experience with preemptive ASA to increase the predicted neo‐LVOT area and its utility with both dedicated TMVR devices and balloon‐expandable valves.
Methods
All patients who underwent ASA for TMVR candidacy in our center between May 2018 and October 2022 and had computed tomography (CT) scans done before and after ASA were included. Each CT was assessed for the minimum predicted neo‐LVOT area at end‐systole, using a virtual valve of the desired TMVR device for each patient. The primary outcome was an increase in the predicted neo‐LVOT area after ASA that was deemed sufficient for safe implantation of the desired TMVR device. The secondary outcome was the absence of acute LVOT obstruction after TMVR.
Results
A total of 12 patients underwent ASA and all but 1 ( n = 11, 91.6%) achieved the primary outcome of having sufficient predicted neo‐LVOT area to proceed with TMVR. The mean increase in neo‐LVOT area after ASA was 126 ± 64 mm 2 (median 119.5, interquartile range: 65.0–163.5 mm 2 ). Two patients (16.7%) required a permanent pacemaker after ASA. Nine patients went on and underwent TMVR with their respective devices and none had LVOT obstruction after the procedure. Among the remaining three patients, one had insufficient neo‐LVOT clearance after ASA, one had unrelated mortality before TMVR, and one had advanced heart failure before TMVR.
Conclusion
In appropriately selected patients and at centers experienced with ASA, preemptive ASA can achieve sufficient neo‐LVOT clearance for TMVR with a variety of devices in approximately 90% of patients.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Advanced Cardiac Valve Center, University of Virginia, Charlottesville, Virginia, USA.
- Department of Cardiology, National Heart Centre Singapore, Singapore City, Singapore.
- Department of Cardiac Surgery, University of Michigan, Ann Arbor, Michigan, USA.
ORCID profiles: Ningyan Wong, Michael Ragosta
Cite
APA
Wong, N., Lim, D. S., Yount, K., Yarboro, L., Ailawadi, G., & Ragosta, M. (2023). Preemptive alcohol septal ablation prior to transcatheter mitral valve replacement. Catheterization and Cardiovascular Interventions, 102(7), 1341-1347. https://doi.org/10.1002/ccd.30879
Vancouver
Wong N, Lim DS, Yount K, Yarboro L, Ailawadi G, Ragosta M. Preemptive alcohol septal ablation prior to transcatheter mitral valve replacement. Catheterization and Cardiovascular Interventions. 2023;102(7):1341-1347. doi:10.1002/ccd.30879
BibTeX
@article{Wong2023,
author = {Wong, Ningyan and Lim, D Scott and Yount, Kenan and Yarboro, Leora and Ailawadi, Gorav and Ragosta, Michael},
title = {Preemptive alcohol septal ablation prior to transcatheter mitral valve replacement},
journal = {Catheterization and Cardiovascular Interventions},
year = {2023},
volume = {102},
number = {7},
pages = {1341--1347},
doi = {10.1002/ccd.30879}
}
EUVIMED